Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Organon (OGN) concluded the recent trading session at $20.18, signifying a +1.05% move from its prior day's close.

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Barclays analyst Balaji Prasad maintained a Buy rating on Organon (OGN – Research Report) today and set a price target of $26.00. The ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Organon & Co (OGN) stock saw a decline, ending the day at $19.97 which represents a decrease of $-0.58 or -2.82% from the prior close of $20.55. The stock opened at $20.51 and touched a low of $19.42 ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

This study aimed at examining the feasibility issues of comparing individualized homeopathic medicines (IHMs) with identical-looking placebos for treating knee osteoarthritis (OA). Forty eligible ...

EY Pune employee's death: Shobha Karandlaje was responding to Rajeev Chandrasekhar's post who called the woman's death very sad and “disturbing at many levels”.

Mirage.News real-time media portal. We acknowledge the traditional owners of country throughout Australia. All timestamps on this site are AEST/AEDT and all times in the articles are local times ...